Click for best price
Cancer Minimal Residual Disease Testing Market Size, Share 2023
Minimal residual disease (MRD) is?a term used to describe the small number of cancer cells in the body after cancer treatment. An MRD positive test result means that disease was still detected after treatment. An MRD negative result means that no disease was detected after treatment.
This report aims to provide a comprehensive presentation of the global market for Cancer Minimal Residual Disease Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Minimal Residual Disease Testing. This report contains market size and forecasts of Cancer Minimal Residual Disease Testing in global, including the following market information:
Global top five Cancer Minimal Residual Disease Testing companies in 2022 (%)
The global Cancer Minimal Residual Disease Testing market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Flow Cytometry Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Cancer Minimal Residual Disease Testing include Adaptive Biotechnologies Corporation, ArcherDX, Inc. (Invitae Corporation), Asuragen, Arup Laboratories, Bio-Rad Laboratories, Cergentis B.V., F. Hoffmann- La Roche Ltd, Guardant Health and ICON plc, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Cancer Minimal Residual Disease Testing manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cancer Minimal Residual Disease Testing Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Cancer Minimal Residual Disease Testing Market Segment Percentages, by Type, 2022 (%)
- Flow Cytometry
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Other
Global Cancer Minimal Residual Disease Testing Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Cancer Minimal Residual Disease Testing Market Segment Percentages, by Application, 2022 (%)
- Hematological Malignancies
- Leukemia
- Lymphoma
- Solid Tumors
- Other
Global Cancer Minimal Residual Disease Testing Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Cancer Minimal Residual Disease Testing Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Cancer Minimal Residual Disease Testing revenues in global market, 2018-2023 (Estimated), ($ millions)
- Key companies Cancer Minimal Residual Disease Testing revenues share in global market, 2022 (%)
- Key companies Cancer Minimal Residual Disease Testing sales in global market, 2018-2023 (Estimated), (K Units)
- Key companies Cancer Minimal Residual Disease Testing sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Adaptive Biotechnologies Corporation
- ArcherDX, Inc. (Invitae Corporation)
- Asuragen
- Arup Laboratories
- Bio-Rad Laboratories
- Cergentis B.V.
- F. Hoffmann- La Roche Ltd
- Guardant Health
- ICON plc
- Invivoscribe
- Laboratory Corporation of America Holdings
- Mission Bio
- Natera, Inc.
- NeoGenomics Laboratories
- Opko Health
- Quest Diagnostics Incorporated
- Sysmex Corporation
- Genetron Health
Outline of Major Chapters:
- Chapter 1: Introduces the definition of Cancer Minimal Residual Disease Testing, market overview.
- Chapter 2: Global Cancer Minimal Residual Disease Testing market size in revenue and volume.
- Chapter 3: Detailed analysis of Cancer Minimal Residual Disease Testing manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
- Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
- Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
- Chapter 6: Sales of Cancer Minimal Residual Disease Testing in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
- Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
- Chapter 8: Global Cancer Minimal Residual Disease Testing capacity by region & country.
- Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
- Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
- Chapter 11: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Cancer Minimal Residual Disease Testing Market, Global Outlook and Forecast 2023-2029 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
118 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Cancer Minimal Residual Disease Testing Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Cancer Minimal Residual Disease Testing Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Cancer Minimal Residual Disease Testing Overall Market Size
2.1 Global Cancer Minimal Residual Disease Testing Market Size: 2022 VS 2029
2.2 Global Cancer Minimal Residual Disease Testing Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Cancer Minimal Residual Disease Testing Sales: 2018-2029
3 Company Landscape
3.1 Top Cancer Minimal Residual Disease Testing Players in Global Market
3.2 Top Global Cancer Minimal Residual Disease Testing Companies Ranked by Revenue
3.3 Global Cancer Minimal Residual Disease Testing Revenue by Companies
3.4 Global Cancer Minimal Residual Disease Testing Sales by Companies
3.5 Global Cancer Minimal Residual Disease Testing Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Cancer Minimal Residual Disease Testing Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Cancer Minimal Residual Disease Testing Product Type
3.8 Tier 1, Tier 2 and Tier 3 Cancer Minimal Residual Disease Testing Players in Global Market
3.8.1 List of Global Tier 1 Cancer Minimal Residual Disease Testing Companies
3.8.2 List of Global Tier 2 and Tier 3 Cancer Minimal Residual Disease Testing Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Cancer Minimal Residual Disease Testing Market Size Markets, 2022 & 2029
4.1.2 Flow Cytometry
4.1.3 Polymerase Chain Reaction (PCR)
4.1.4 Next-Generation Sequencing (NGS)
4.1.5 Other
4.2 By Type - Global Cancer Minimal Residual Disease Testing Revenue & Forecasts
4.2.1 By Type - Global Cancer Minimal Residual Disease Testing Revenue, 2018-2023
4.2.2 By Type - Global Cancer Minimal Residual Disease Testing Revenue, 2024-2029
4.2.3 By Type - Global Cancer Minimal Residual Disease Testing Revenue Market Share, 2018-2029
4.3 By Type - Global Cancer Minimal Residual Disease Testing Sales & Forecasts
4.3.1 By Type - Global Cancer Minimal Residual Disease Testing Sales, 2018-2023
4.3.2 By Type - Global Cancer Minimal Residual Disease Testing Sales, 2024-2029
4.3.3 By Type - Global Cancer Minimal Residual Disease Testing Sales Market Share, 2018-2029
4.4 By Type - Global Cancer Minimal Residual Disease Testing Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Cancer Minimal Residual Disease Testing Market Size, 2022 & 2029
5.1.2 Hematological Malignancies
5.1.3 Leukemia
5.1.4 Lymphoma
5.1.5 Solid Tumors
5.1.6 Other
5.2 By Application - Global Cancer Minimal Residual Disease Testing Revenue & Forecasts
5.2.1 By Application - Global Cancer Minimal Residual Disease Testing Revenue, 2018-2023
5.2.2 By Application - Global Cancer Minimal Residual Disease Testing Revenue, 2024-2029
5.2.3 By Application - Global Cancer Minimal Residual Disease Testing Revenue Market Share, 2018-2029
5.3 By Application - Global Cancer Minimal Residual Disease Testing Sales & Forecasts
5.3.1 By Application - Global Cancer Minimal Residual Disease Testing Sales, 2018-2023
5.3.2 By Application - Global Cancer Minimal Residual Disease Testing Sales, 2024-2029
5.3.3 By Application - Global Cancer Minimal Residual Disease Testing Sales Market Share, 2018-2029
5.4 By Application - Global Cancer Minimal Residual Disease Testing Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Cancer Minimal Residual Disease Testing Market Size, 2022 & 2029
6.2 By Region - Global Cancer Minimal Residual Disease Testing Revenue & Forecasts
6.2.1 By Region - Global Cancer Minimal Residual Disease Testing Revenue, 2018-2023
6.2.2 By Region - Global Cancer Minimal Residual Disease Testing Revenue, 2024-2029
6.2.3 By Region - Global Cancer Minimal Residual Disease Testing Revenue Market Share, 2018-2029
6.3 By Region - Global Cancer Minimal Residual Disease Testing Sales & Forecasts
6.3.1 By Region - Global Cancer Minimal Residual Disease Testing Sales, 2018-2023
6.3.2 By Region - Global Cancer Minimal Residual Disease Testing Sales, 2024-2029
6.3.3 By Region - Global Cancer Minimal Residual Disease Testing Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Cancer Minimal Residual Disease Testing Revenue, 2018-2029
6.4.2 By Country - North America Cancer Minimal Residual Disease Testing Sales, 2018-2029
6.4.3 US Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.4.4 Canada Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.4.5 Mexico Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Cancer Minimal Residual Disease Testing Revenue, 2018-2029
6.5.2 By Country - Europe Cancer Minimal Residual Disease Testing Sales, 2018-2029
6.5.3 Germany Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.5.4 France Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.5.5 U.K. Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.5.6 Italy Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.5.7 Russia Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.5.8 Nordic Countries Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.5.9 Benelux Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Cancer Minimal Residual Disease Testing Revenue, 2018-2029
6.6.2 By Region - Asia Cancer Minimal Residual Disease Testing Sales, 2018-2029
6.6.3 China Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.6.4 Japan Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.6.5 South Korea Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.6.6 Southeast Asia Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.6.7 India Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Cancer Minimal Residual Disease Testing Revenue, 2018-2029
6.7.2 By Country - South America Cancer Minimal Residual Disease Testing Sales, 2018-2029
6.7.3 Brazil Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.7.4 Argentina Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Cancer Minimal Residual Disease Testing Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Cancer Minimal Residual Disease Testing Sales, 2018-2029
6.8.3 Turkey Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.8.4 Israel Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.8.5 Saudi Arabia Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.8.6 UAE Cancer Minimal Residual Disease Testing Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Adaptive Biotechnologies Corporation
7.1.1 Adaptive Biotechnologies Corporation Company Summary
7.1.2 Adaptive Biotechnologies Corporation Business Overview
7.1.3 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Major Product Offerings
7.1.4 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.1.5 Adaptive Biotechnologies Corporation Key News & Latest Developments
7.2 ArcherDX, Inc. (Invitae Corporation)
7.2.1 ArcherDX, Inc. (Invitae Corporation) Company Summary
7.2.2 ArcherDX, Inc. (Invitae Corporation) Business Overview
7.2.3 ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Major Product Offerings
7.2.4 ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.2.5 ArcherDX, Inc. (Invitae Corporation) Key News & Latest Developments
7.3 Asuragen
7.3.1 Asuragen Company Summary
7.3.2 Asuragen Business Overview
7.3.3 Asuragen Cancer Minimal Residual Disease Testing Major Product Offerings
7.3.4 Asuragen Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.3.5 Asuragen Key News & Latest Developments
7.4 Arup Laboratories
7.4.1 Arup Laboratories Company Summary
7.4.2 Arup Laboratories Business Overview
7.4.3 Arup Laboratories Cancer Minimal Residual Disease Testing Major Product Offerings
7.4.4 Arup Laboratories Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.4.5 Arup Laboratories Key News & Latest Developments
7.5 Bio-Rad Laboratories
7.5.1 Bio-Rad Laboratories Company Summary
7.5.2 Bio-Rad Laboratories Business Overview
7.5.3 Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Major Product Offerings
7.5.4 Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.5.5 Bio-Rad Laboratories Key News & Latest Developments
7.6 Cergentis B.V.
7.6.1 Cergentis B.V. Company Summary
7.6.2 Cergentis B.V. Business Overview
7.6.3 Cergentis B.V. Cancer Minimal Residual Disease Testing Major Product Offerings
7.6.4 Cergentis B.V. Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.6.5 Cergentis B.V. Key News & Latest Developments
7.7 F. Hoffmann- La Roche Ltd
7.7.1 F. Hoffmann- La Roche Ltd Company Summary
7.7.2 F. Hoffmann- La Roche Ltd Business Overview
7.7.3 F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Major Product Offerings
7.7.4 F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.7.5 F. Hoffmann- La Roche Ltd Key News & Latest Developments
7.8 Guardant Health
7.8.1 Guardant Health Company Summary
7.8.2 Guardant Health Business Overview
7.8.3 Guardant Health Cancer Minimal Residual Disease Testing Major Product Offerings
7.8.4 Guardant Health Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.8.5 Guardant Health Key News & Latest Developments
7.9 ICON plc
7.9.1 ICON plc Company Summary
7.9.2 ICON plc Business Overview
7.9.3 ICON plc Cancer Minimal Residual Disease Testing Major Product Offerings
7.9.4 ICON plc Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.9.5 ICON plc Key News & Latest Developments
7.10 Invivoscribe
7.10.1 Invivoscribe Company Summary
7.10.2 Invivoscribe Business Overview
7.10.3 Invivoscribe Cancer Minimal Residual Disease Testing Major Product Offerings
7.10.4 Invivoscribe Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.10.5 Invivoscribe Key News & Latest Developments
7.11 Laboratory Corporation of America Holdings
7.11.1 Laboratory Corporation of America Holdings Company Summary
7.11.2 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Business Overview
7.11.3 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Major Product Offerings
7.11.4 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.11.5 Laboratory Corporation of America Holdings Key News & Latest Developments
7.12 Mission Bio
7.12.1 Mission Bio Company Summary
7.12.2 Mission Bio Cancer Minimal Residual Disease Testing Business Overview
7.12.3 Mission Bio Cancer Minimal Residual Disease Testing Major Product Offerings
7.12.4 Mission Bio Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.12.5 Mission Bio Key News & Latest Developments
7.13 Natera, Inc.
7.13.1 Natera, Inc. Company Summary
7.13.2 Natera, Inc. Cancer Minimal Residual Disease Testing Business Overview
7.13.3 Natera, Inc. Cancer Minimal Residual Disease Testing Major Product Offerings
7.13.4 Natera, Inc. Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.13.5 Natera, Inc. Key News & Latest Developments
7.14 NeoGenomics Laboratories
7.14.1 NeoGenomics Laboratories Company Summary
7.14.2 NeoGenomics Laboratories Business Overview
7.14.3 NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Major Product Offerings
7.14.4 NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.14.5 NeoGenomics Laboratories Key News & Latest Developments
7.15 Opko Health
7.15.1 Opko Health Company Summary
7.15.2 Opko Health Business Overview
7.15.3 Opko Health Cancer Minimal Residual Disease Testing Major Product Offerings
7.15.4 Opko Health Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.15.5 Opko Health Key News & Latest Developments
7.16 Quest Diagnostics Incorporated
7.16.1 Quest Diagnostics Incorporated Company Summary
7.16.2 Quest Diagnostics Incorporated Business Overview
7.16.3 Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Major Product Offerings
7.16.4 Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.16.5 Quest Diagnostics Incorporated Key News & Latest Developments
7.17 Sysmex Corporation
7.17.1 Sysmex Corporation Company Summary
7.17.2 Sysmex Corporation Business Overview
7.17.3 Sysmex Corporation Cancer Minimal Residual Disease Testing Major Product Offerings
7.17.4 Sysmex Corporation Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.17.5 Sysmex Corporation Key News & Latest Developments
7.18 Genetron Health
7.18.1 Genetron Health Company Summary
7.18.2 Genetron Health Business Overview
7.18.3 Genetron Health Cancer Minimal Residual Disease Testing Major Product Offerings
7.18.4 Genetron Health Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.18.5 Genetron Health Key News & Latest Developments
8 Global Cancer Minimal Residual Disease Testing Production Capacity, Analysis
8.1 Global Cancer Minimal Residual Disease Testing Production Capacity, 2018-2029
8.2 Cancer Minimal Residual Disease Testing Production Capacity of Key Manufacturers in Global Market
8.3 Global Cancer Minimal Residual Disease Testing Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Cancer Minimal Residual Disease Testing Supply Chain Analysis
10.1 Cancer Minimal Residual Disease Testing Industry Value Chain
10.2 Cancer Minimal Residual Disease Testing Upstream Market
10.3 Cancer Minimal Residual Disease Testing Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Cancer Minimal Residual Disease Testing Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Cancer Minimal Residual Disease Testing in Global Market
Table 2. Top Cancer Minimal Residual Disease Testing Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Cancer Minimal Residual Disease Testing Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Cancer Minimal Residual Disease Testing Revenue Share by Companies, 2018-2023
Table 5. Global Cancer Minimal Residual Disease Testing Sales by Companies, (K Units), 2018-2023
Table 6. Global Cancer Minimal Residual Disease Testing Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Cancer Minimal Residual Disease Testing Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Cancer Minimal Residual Disease Testing Product Type
Table 9. List of Global Tier 1 Cancer Minimal Residual Disease Testing Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Cancer Minimal Residual Disease Testing Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Cancer Minimal Residual Disease Testing Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Cancer Minimal Residual Disease Testing Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Cancer Minimal Residual Disease Testing Sales (K Units), 2018-2023
Table 15. By Type - Global Cancer Minimal Residual Disease Testing Sales (K Units), 2024-2029
Table 16. By Application ? Global Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Cancer Minimal Residual Disease Testing Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Cancer Minimal Residual Disease Testing Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Cancer Minimal Residual Disease Testing Sales (K Units), 2018-2023
Table 20. By Application - Global Cancer Minimal Residual Disease Testing Sales (K Units), 2024-2029
Table 21. By Region ? Global Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Cancer Minimal Residual Disease Testing Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Cancer Minimal Residual Disease Testing Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Cancer Minimal Residual Disease Testing Sales (K Units), 2018-2023
Table 25. By Region - Global Cancer Minimal Residual Disease Testing Sales (K Units), 2024-2029
Table 26. By Country - North America Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Cancer Minimal Residual Disease Testing Sales, (K Units), 2018-2023
Table 29. By Country - North America Cancer Minimal Residual Disease Testing Sales, (K Units), 2024-2029
Table 30. By Country - Europe Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Cancer Minimal Residual Disease Testing Sales, (K Units), 2018-2023
Table 33. By Country - Europe Cancer Minimal Residual Disease Testing Sales, (K Units), 2024-2029
Table 34. By Region - Asia Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Cancer Minimal Residual Disease Testing Sales, (K Units), 2018-2023
Table 37. By Region - Asia Cancer Minimal Residual Disease Testing Sales, (K Units), 2024-2029
Table 38. By Country - South America Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Cancer Minimal Residual Disease Testing Sales, (K Units), 2018-2023
Table 41. By Country - South America Cancer Minimal Residual Disease Testing Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Cancer Minimal Residual Disease Testing Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Cancer Minimal Residual Disease Testing Sales, (K Units), 2024-2029
Table 46. Adaptive Biotechnologies Corporation Company Summary
Table 47. Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Product Offerings
Table 48. Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. Adaptive Biotechnologies Corporation Key News & Latest Developments
Table 50. ArcherDX, Inc. (Invitae Corporation) Company Summary
Table 51. ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Product Offerings
Table 52. ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. ArcherDX, Inc. (Invitae Corporation) Key News & Latest Developments
Table 54. Asuragen Company Summary
Table 55. Asuragen Cancer Minimal Residual Disease Testing Product Offerings
Table 56. Asuragen Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. Asuragen Key News & Latest Developments
Table 58. Arup Laboratories Company Summary
Table 59. Arup Laboratories Cancer Minimal Residual Disease Testing Product Offerings
Table 60. Arup Laboratories Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. Arup Laboratories Key News & Latest Developments
Table 62. Bio-Rad Laboratories Company Summary
Table 63. Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Product Offerings
Table 64. Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. Bio-Rad Laboratories Key News & Latest Developments
Table 66. Cergentis B.V. Company Summary
Table 67. Cergentis B.V. Cancer Minimal Residual Disease Testing Product Offerings
Table 68. Cergentis B.V. Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. Cergentis B.V. Key News & Latest Developments
Table 70. F. Hoffmann- La Roche Ltd Company Summary
Table 71. F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Product Offerings
Table 72. F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. F. Hoffmann- La Roche Ltd Key News & Latest Developments
Table 74. Guardant Health Company Summary
Table 75. Guardant Health Cancer Minimal Residual Disease Testing Product Offerings
Table 76. Guardant Health Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. Guardant Health Key News & Latest Developments
Table 78. ICON plc Company Summary
Table 79. ICON plc Cancer Minimal Residual Disease Testing Product Offerings
Table 80. ICON plc Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. ICON plc Key News & Latest Developments
Table 82. Invivoscribe Company Summary
Table 83. Invivoscribe Cancer Minimal Residual Disease Testing Product Offerings
Table 84. Invivoscribe Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 85. Invivoscribe Key News & Latest Developments
Table 86. Laboratory Corporation of America Holdings Company Summary
Table 87. Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Product Offerings
Table 88. Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 89. Laboratory Corporation of America Holdings Key News & Latest Developments
Table 90. Mission Bio Company Summary
Table 91. Mission Bio Cancer Minimal Residual Disease Testing Product Offerings
Table 92. Mission Bio Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 93. Mission Bio Key News & Latest Developments
Table 94. Natera, Inc. Company Summary
Table 95. Natera, Inc. Cancer Minimal Residual Disease Testing Product Offerings
Table 96. Natera, Inc. Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 97. Natera, Inc. Key News & Latest Developments
Table 98. NeoGenomics Laboratories Company Summary
Table 99. NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Product Offerings
Table 100. NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 101. NeoGenomics Laboratories Key News & Latest Developments
Table 102. Opko Health Company Summary
Table 103. Opko Health Cancer Minimal Residual Disease Testing Product Offerings
Table 104. Opko Health Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 105. Opko Health Key News & Latest Developments
Table 106. Quest Diagnostics Incorporated Company Summary
Table 107. Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Product Offerings
Table 108. Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 109. Quest Diagnostics Incorporated Key News & Latest Developments
Table 110. Sysmex Corporation Company Summary
Table 111. Sysmex Corporation Cancer Minimal Residual Disease Testing Product Offerings
Table 112. Sysmex Corporation Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 113. Sysmex Corporation Key News & Latest Developments
Table 114. Genetron Health Company Summary
Table 115. Genetron Health Cancer Minimal Residual Disease Testing Product Offerings
Table 116. Genetron Health Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 117. Genetron Health Key News & Latest Developments
Table 118. Cancer Minimal Residual Disease Testing Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 119. Global Cancer Minimal Residual Disease Testing Capacity Market Share of Key Manufacturers, 2021-2023
Table 120. Global Cancer Minimal Residual Disease Testing Production by Region, 2018-2023 (K Units)
Table 121. Global Cancer Minimal Residual Disease Testing Production by Region, 2024-2029 (K Units)
Table 122. Cancer Minimal Residual Disease Testing Market Opportunities & Trends in Global Market
Table 123. Cancer Minimal Residual Disease Testing Market Drivers in Global Market
Table 124. Cancer Minimal Residual Disease Testing Market Restraints in Global Market
Table 125. Cancer Minimal Residual Disease Testing Raw Materials
Table 126. Cancer Minimal Residual Disease Testing Raw Materials Suppliers in Global Market
Table 127. Typical Cancer Minimal Residual Disease Testing Downstream
Table 128. Cancer Minimal Residual Disease Testing Downstream Clients in Global Market
Table 129. Cancer Minimal Residual Disease Testing Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Cancer Minimal Residual Disease Testing Segment by Type in 2022
Figure 2. Cancer Minimal Residual Disease Testing Segment by Application in 2022
Figure 3. Global Cancer Minimal Residual Disease Testing Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Cancer Minimal Residual Disease Testing Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Cancer Minimal Residual Disease Testing Revenue, 2018-2029 (US$, Mn)
Figure 7. Cancer Minimal Residual Disease Testing Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Cancer Minimal Residual Disease Testing Revenue in 2022
Figure 9. By Type - Global Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Cancer Minimal Residual Disease Testing Revenue Market Share, 2018-2029
Figure 11. By Type - Global Cancer Minimal Residual Disease Testing Sales Market Share, 2018-2029
Figure 12. By Type - Global Cancer Minimal Residual Disease Testing Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Cancer Minimal Residual Disease Testing Revenue Market Share, 2018-2029
Figure 15. By Application - Global Cancer Minimal Residual Disease Testing Sales Market Share, 2018-2029
Figure 16. By Application - Global Cancer Minimal Residual Disease Testing Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Cancer Minimal Residual Disease Testing Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Cancer Minimal Residual Disease Testing Revenue Market Share, 2018-2029
Figure 20. By Region - Global Cancer Minimal Residual Disease Testing Sales Market Share, 2018-2029
Figure 21. By Country - North America Cancer Minimal Residual Disease Testing Revenue Market Share, 2018-2029
Figure 22. By Country - North America Cancer Minimal Residual Disease Testing Sales Market Share, 2018-2029
Figure 23. US Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Cancer Minimal Residual Disease Testing Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Cancer Minimal Residual Disease Testing Sales Market Share, 2018-2029
Figure 28. Germany Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2029
Figure 29. France Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Cancer Minimal Residual Disease Testing Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Cancer Minimal Residual Disease Testing Sales Market Share, 2018-2029
Figure 37. China Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2029
Figure 41. India Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Cancer Minimal Residual Disease Testing Revenue Market Share, 2018-2029
Figure 43. By Country - South America Cancer Minimal Residual Disease Testing Sales Market Share, 2018-2029
Figure 44. Brazil Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Cancer Minimal Residual Disease Testing Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Cancer Minimal Residual Disease Testing Sales Market Share, 2018-2029
Figure 48. Turkey Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Cancer Minimal Residual Disease Testing Revenue, (US$, Mn), 2018-2029
Figure 52. Global Cancer Minimal Residual Disease Testing Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Cancer Minimal Residual Disease Testing by Region, 2022 VS 2029
Figure 54. Cancer Minimal Residual Disease Testing Industry Value Chain
Figure 55. Marketing Channels
